Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Paul Chervinsky, Thomas Casale, Robert Townley, Ita Tripathy, Simon Hedgecock, Angel Fowler-Taylor, Henry Shen, Howard Fox

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Background: Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. Objective: To investigate the efficacy, safety, and tolerability of omalizumab in the treatment of perennial allergic rhinitis (PAR). Methods: Two hundred eighty-nine patients (aged 12 to 70 years) with moderate-to-severe symptomatic PAR were randomized to 16 weeks' double-blind subcutaneous treatment with either placebo (n = 145) or omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks; n = 144). The primary efficacy variable was the mean daily nasal severity score, as determined from patient daily diary cards. Secondary efficacy variables included use of rescue antihistamine, rhinoconjunctivitis-specific quality of life (RQoL), and patients' evaluation of treatment efficacy. Safety and tolerability were evaluated from adverse event reports and laboratory safety parameters. Results: Throughout 16 weeks of treatment, the mean daily nasal severity score was significantly lower in omalizumab-treated patients than with placebo (P <0.001). The improvement in symptoms when taking omalizumab was paralleled by a reduction in use of rescue antihistamine (P ≤ 0.005 overall) and improved RQoL relative to placebo. Patients' evaluation of treatment efficacy significantly favored omalizumab over placebo (P = 0.001). Omalizumab therapy was well tolerated. There were no safety concerns. Conclusions: Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.

Original languageEnglish
Pages (from-to)160-167
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume91
Issue number2
StatePublished - Aug 1 2003

Fingerprint

Rhinitis, Allergic, Perennial
Histamine Antagonists
Placebos
Quality of Life
Safety
Therapeutics
Nose
Seasonal Allergic Rhinitis
Omalizumab
anti-IgE antibodies
Immunoglobulin E

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Chervinsky, P., Casale, T., Townley, R., Tripathy, I., Hedgecock, S., Fowler-Taylor, A., ... Fox, H. (2003). Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Annals of Allergy, Asthma and Immunology, 91(2), 160-167.

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. / Chervinsky, Paul; Casale, Thomas; Townley, Robert; Tripathy, Ita; Hedgecock, Simon; Fowler-Taylor, Angel; Shen, Henry; Fox, Howard.

In: Annals of Allergy, Asthma and Immunology, Vol. 91, No. 2, 01.08.2003, p. 160-167.

Research output: Contribution to journalArticle

Chervinsky, P, Casale, T, Townley, R, Tripathy, I, Hedgecock, S, Fowler-Taylor, A, Shen, H & Fox, H 2003, 'Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis', Annals of Allergy, Asthma and Immunology, vol. 91, no. 2, pp. 160-167.
Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Annals of Allergy, Asthma and Immunology. 2003 Aug 1;91(2):160-167.
Chervinsky, Paul ; Casale, Thomas ; Townley, Robert ; Tripathy, Ita ; Hedgecock, Simon ; Fowler-Taylor, Angel ; Shen, Henry ; Fox, Howard. / Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. In: Annals of Allergy, Asthma and Immunology. 2003 ; Vol. 91, No. 2. pp. 160-167.
@article{71a59a439a9f47a4889e05cf20fbfcfc,
title = "Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis",
abstract = "Background: Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. Objective: To investigate the efficacy, safety, and tolerability of omalizumab in the treatment of perennial allergic rhinitis (PAR). Methods: Two hundred eighty-nine patients (aged 12 to 70 years) with moderate-to-severe symptomatic PAR were randomized to 16 weeks' double-blind subcutaneous treatment with either placebo (n = 145) or omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks; n = 144). The primary efficacy variable was the mean daily nasal severity score, as determined from patient daily diary cards. Secondary efficacy variables included use of rescue antihistamine, rhinoconjunctivitis-specific quality of life (RQoL), and patients' evaluation of treatment efficacy. Safety and tolerability were evaluated from adverse event reports and laboratory safety parameters. Results: Throughout 16 weeks of treatment, the mean daily nasal severity score was significantly lower in omalizumab-treated patients than with placebo (P <0.001). The improvement in symptoms when taking omalizumab was paralleled by a reduction in use of rescue antihistamine (P ≤ 0.005 overall) and improved RQoL relative to placebo. Patients' evaluation of treatment efficacy significantly favored omalizumab over placebo (P = 0.001). Omalizumab therapy was well tolerated. There were no safety concerns. Conclusions: Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.",
author = "Paul Chervinsky and Thomas Casale and Robert Townley and Ita Tripathy and Simon Hedgecock and Angel Fowler-Taylor and Henry Shen and Howard Fox",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "91",
pages = "160--167",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "2",

}

TY - JOUR

T1 - Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

AU - Chervinsky, Paul

AU - Casale, Thomas

AU - Townley, Robert

AU - Tripathy, Ita

AU - Hedgecock, Simon

AU - Fowler-Taylor, Angel

AU - Shen, Henry

AU - Fox, Howard

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. Objective: To investigate the efficacy, safety, and tolerability of omalizumab in the treatment of perennial allergic rhinitis (PAR). Methods: Two hundred eighty-nine patients (aged 12 to 70 years) with moderate-to-severe symptomatic PAR were randomized to 16 weeks' double-blind subcutaneous treatment with either placebo (n = 145) or omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks; n = 144). The primary efficacy variable was the mean daily nasal severity score, as determined from patient daily diary cards. Secondary efficacy variables included use of rescue antihistamine, rhinoconjunctivitis-specific quality of life (RQoL), and patients' evaluation of treatment efficacy. Safety and tolerability were evaluated from adverse event reports and laboratory safety parameters. Results: Throughout 16 weeks of treatment, the mean daily nasal severity score was significantly lower in omalizumab-treated patients than with placebo (P <0.001). The improvement in symptoms when taking omalizumab was paralleled by a reduction in use of rescue antihistamine (P ≤ 0.005 overall) and improved RQoL relative to placebo. Patients' evaluation of treatment efficacy significantly favored omalizumab over placebo (P = 0.001). Omalizumab therapy was well tolerated. There were no safety concerns. Conclusions: Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.

AB - Background: Treatment with omalizumab, an anti-IgE antibody, improves symptoms and quality of life in patients with seasonal allergic rhinitis but has not previously been investigated in patients with perennial symptoms. Objective: To investigate the efficacy, safety, and tolerability of omalizumab in the treatment of perennial allergic rhinitis (PAR). Methods: Two hundred eighty-nine patients (aged 12 to 70 years) with moderate-to-severe symptomatic PAR were randomized to 16 weeks' double-blind subcutaneous treatment with either placebo (n = 145) or omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks; n = 144). The primary efficacy variable was the mean daily nasal severity score, as determined from patient daily diary cards. Secondary efficacy variables included use of rescue antihistamine, rhinoconjunctivitis-specific quality of life (RQoL), and patients' evaluation of treatment efficacy. Safety and tolerability were evaluated from adverse event reports and laboratory safety parameters. Results: Throughout 16 weeks of treatment, the mean daily nasal severity score was significantly lower in omalizumab-treated patients than with placebo (P <0.001). The improvement in symptoms when taking omalizumab was paralleled by a reduction in use of rescue antihistamine (P ≤ 0.005 overall) and improved RQoL relative to placebo. Patients' evaluation of treatment efficacy significantly favored omalizumab over placebo (P = 0.001). Omalizumab therapy was well tolerated. There were no safety concerns. Conclusions: Omalizumab was safe and well tolerated in the treatment of patients with PAR, providing effective control of symptoms and improved RQoL while simultaneously minimizing reliance on rescue antihistamines.

UR - http://www.scopus.com/inward/record.url?scp=0041737745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041737745&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 160

EP - 167

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 2

ER -